Reviews & Editorials on I-SPY 2
<span data-metadata=""><span data-buffer="">Reinventing clinical trials
Laura Esserman’s 2015 lecture at ‘Exponential Medicine’ discussed the re-engineering of clinical trials, inspired by the insights of late Intel CEO Andy Grove into the differences between development in the semiconductor industry and healthcare.
Length: 26:50 min
Changing strategies in the 'war on cancer'
Dr. Angela DiMichele, Professor of Medicine and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania and I-SPY 2 Site Operations Working Group Chair discusses the innovations of I-SPY 2 and testing of new antibody-drug conjugates.
Length: 34:32 min
I-SPY Clinical Trials:
An interview with Dr. Laura Esserman
The ground-breaking I-SPY 2 trial of neoadjuvant treatment for locally advanced breast cancer established a new benchmark for efficiency of phase II clinical trials. Widely regarded as a pioneer of the ‘platform’ trial, I-SPY 2’s success continues to be a major influence on the development of next-generation trial designs in oncology and beyond.
